Cupron® Introduces Revolutionary, Cost-effective Antimicrobial Technology, Cupron Sinerji™

Cupron®, a renowned antimicrobial solutions provider – doing business as Cupron Performance Additives – is excited to announce the significant expansion of its offerings with the introduction of Cupron Sinerji™. This new adjuvant-enhanced platform offers superior antimicrobial efficacy across multiple substrates, all while maintaining an economical cost structure.

Cupron Sinerji incorporates adjuvants into the copper-based formulation, resulting in a custom, flexible technology engineered to harness synergistic effects to meet a wide range of product protection and antimicrobial performance objectives – from US EPA Treated Article Exemptions to unique and differentiated Public Health Claims.

Utilizing adjuvants, the technology delivers heightened efficacy against various organisms, improves color selection, and increases manufacturing yields. It offers an efficient and adaptable solution for numerous markets and applications, demonstrating its versatility and innovative potential across all polymers and organisms.

“The high prices of silver additives have previously compelled many brands to restrict their use in product manufacturing, subsequently diminishing the antimicrobial potency of the final products,” said Chris Andrews, CEO of Cupron Performances Additives. “However, Cupron Sinerji’s competitive cost to performance ratio is set to revolutionize traditional views on the value of antimicrobial solutions, introducing them to new applications that were previously considered cost-prohibitive.”

Cupron Sinerji has an attractive sustainability profile as the foundation of the platform is recycled copper and the technology is non-leaching. As a recognized micronutrient, copper presents a benign regulatory profile unlike other metal-ion (e.g. silver) or organic (e.g. ZnPT, PHMB, IPBC, etc.) alternatives under scrutiny in the marketplace.

Cupron Performance Additives is engaged with current sales and distribution partners to make the Cupron Sinerji technology platform available to their customers, and will add additional partners seeking to bring new additives to the commercial and industrial sectors.


Learn more here.

Recent News


Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced that it has signed a research agreement with The School of Pharmacy at University College Cork, Ireland. The scope of the agreement encompasses the development of novel topical formulations of Rapamycin (sirolimus) as potential


KeViRx, Inc. Awarded $1.99 Million

KeViRx, Inc., an innovative, early-stage pharmaceutical company, announced today the receipt of $1.99 million in grant funding from the U.S. Department of Defense’s Peer Reviewed Medical Research Program. This grant funding will allow KeViRx to advance its first-in-class small molecule platform technology, KVX-053, toward IND for pulmonary microvascular leakage and inflammation during acute lung injury


Virginia Catalyst Announces Round 17 of Grant Funding

The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it is accepting letters of intent (LOI) for Grant Round 16 to fund the development and commercialization of life science projects that address major unmet needs for improving human health and advance Virginia’s economy. “The mission of the Catalyst